Reviewing Puma Biotechnology (PBYI) and Its Rivals

Puma Biotechnology (NASDAQ: PBYI) is one of 188 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it contrast to its peers? We will compare Puma Biotechnology to similar companies based on the strength of its earnings, risk, institutional ownership, dividends, profitability, analyst recommendations and valuation.

Institutional & Insider Ownership

96.0% of Puma Biotechnology shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 21.1% of Puma Biotechnology shares are held by insiders. Comparatively, 14.7% of shares of all “Biotechnology & Medical Research” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Puma Biotechnology and its peers, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Puma Biotechnology 0 1 8 0 2.89
Puma Biotechnology Competitors 665 2523 6742 134 2.63

Puma Biotechnology currently has a consensus target price of $130.67, suggesting a potential upside of 31.65%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 11.94%. Given Puma Biotechnology’s stronger consensus rating and higher probable upside, research analysts plainly believe Puma Biotechnology is more favorable than its peers.

Profitability

This table compares Puma Biotechnology and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Puma Biotechnology N/A -208.58% -145.91%
Puma Biotechnology Competitors -4,408.50% -470.69% -41.97%

Volatility and Risk

Puma Biotechnology has a beta of 0.72, indicating that its stock price is 28% less volatile than the S&P 500. Comparatively, Puma Biotechnology’s peers have a beta of 1.50, indicating that their average stock price is 50% more volatile than the S&P 500.

Valuation and Earnings

This table compares Puma Biotechnology and its peers revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Puma Biotechnology N/A -$276.01 million -12.13
Puma Biotechnology Competitors $217.40 million -$39.40 million -64.88

Puma Biotechnology’s peers have higher revenue and earnings than Puma Biotechnology. Puma Biotechnology is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Summary

Puma Biotechnology beats its peers on 7 of the 12 factors compared.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors (EGFRs), HER1, HER2 and HER4. Its initial focus is on the development of neratinib as an oral treatment of patients with HER2 positive metastatic breast cancer. It focuses on developing neratinib as an intravenously administered agent. The intravenous version of neratinib resulted in exposure levels of neratinib in pre-clinical models. Its product candidate, PB357, is an orally administered agent that is an irreversible TKI that blocks signal transduction through the epidermal growth factor receptors.

Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply